LIDOCAINE HYDROCHLORIDE ORAL TOPICAL SOLUTION USP, 2% (Viscous)

/LIDOCAINE HYDROCHLORIDE ORAL TOPICAL SOLUTION USP, 2% (Viscous)
LIDOCAINE HYDROCHLORIDE ORAL TOPICAL SOLUTION USP, 2% (Viscous)2018-09-06T09:12:40+00:00

Prescription Drug Name:

LIDOCAINE HYDROCHLORIDE ORAL TOPICAL SOLUTION USP, 2% (Viscous)

ID:

3c37691d-5bdf-4208-a30a-8b4ba17e765f

Code:

34391-3

DESCRIPTION


id: 8b2b1533-fde3-4bb4-9143-36a8e755a47d
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Lidocaine hydrochloride oral topical solution USP, 2% (viscous) contains a local anesthetic agent and is administered topically. Lidocaine hydrochloride oral topical solution USP, 2% (viscous) contains lidocaine HCl, which is chemically designated as acetamide, 2-(diethylamino)- -(2,6-dimethylphenyl)-, monohydrochloride and has the following structural formula:
N
The molecular formula of lidocaine is C H N O. The molecular weight is 234.34.
14
22
2

INDICATIONS AND USAGE


id: 6ff0da34-9b05-4d1e-8b62-46877ae95d4b
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Lidocaine hydrochloride oral topical solution USP, 2% (viscous) is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.

CONTRAINDICATIONS


id: 5a460b69-f752-4d91-9c5d-bcfb50ba36b1
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of the solution.

WARNINGS


id: 5f4efc73-5af2-423b-abca-d9479e85b299
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT. THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS. Lidocaine hydrochloride oral topical solution, 2% (viscous) should be used with extreme caution if the mucosa in the area of application has been traumatized, since under such conditions there is the potential for rapid systemic absorption. Post marketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of lidocaine hydrochloride oral topical solution 2% (viscous) when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, lidocaine hydrochloride oral topical solution 2% (viscous) should generally not be used. For other conditions, the use of the product in patients less than 3 years of age should be limited to those situations where safer alternatives are not available or have been tried but failed.

Life-threatening and fatal events in infants and young children


ADVERSE REACTIONS


id: 73c01184-f25b-422d-b3d2-03f3fa1e98cc
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Adverse experiences following the administration of lidocaine are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy, or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported: Central Nervous System: CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of lidocaine is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption. Cardiovascular System: Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest. Allergic: Allergic reactions are characterized by cutaneous lesions, urticaria, edema, or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to the local anesthetic agent or to the methylparaben and/or propylparaben used in this formulation. Allergic reactions as a result of sensitivity to lidocaine are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.

OVERDOSAGE


id: a0251b84-d82b-4997-8642-30f9ca41aae0
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics (see , , and ).
ADVERSE REACTIONS
WARNINGS
PRECAUTIONS

HOW SUPPLIED


id: d2cc0ba1-9d33-431d-95e3-0ed7e405fece
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

NDC:50436-1827-1 in a BOTTLE of 100 SOLUTIONS

LIDOCAINE HYDROCHLORIDE SOLUTION


id: f1607c02-37e2-428d-996b-ecf296da7d17
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4